Literature DB >> 33894833

Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial.

Vinh Q Dang1, Lan N Vuong2, Tam M Luu3, Toan D Pham4, Tuong M Ho5, Anh N Ha3, Binh T Truong6, Anh K Phan3, Dung P Nguyen3, Thanh N Pham6, Quan T Pham4, Rui Wang7, Robert J Norman8, Ben W Mol9.   

Abstract

BACKGROUND: The use of intracytoplasmic sperm injection has increased substantially worldwide, primarily in couples with non-male factor infertility. However, there is a paucity of evidence from randomised trials supporting this approach compared with conventional in-vitro fertilisation (IVF). We aimed to investigate whether intracytoplasmic sperm injection would result in a higher livebirth rate compared with conventional IVF.
METHODS: This open-label, multicentre, randomised trial was done at two IVF centres in Ho Chi Minh City, Vietnam (IVFMD, My Duc Hospital and IVFAS, An Sinh Hospital). Eligible couples were aged at least 18 years and the male partner's sperm count and motility (progressive motility) were normal based on WHO 2010 criteria. Couples had to have undergone two or fewer previous conventional IVF or intracytoplasmic sperm injection attempts, have used an antagonist protocol for ovarian stimulation, and agree to have two or fewer embryos transferred. Couples were randomly assigned (1:1) to undergo either intracytoplasmic sperm injection or conventional IVF, using block randomisation with variable block size of 2, 4, or 8 and a telephone-based central randomisation method. The computer-generated randomisation list was prepared by an independent statistician who had no other involvement in the study. Embryologists and couples were not masked to study groups because of the type of interventions and differences in hospital fees, but clinicians performing embryo transfer were unaware of study group allocation. The primary outcome was livebirth after the first embryo transfer from the initiated cycle. Analyses were done on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov, NCT03428919.
FINDINGS: Between March 16, 2018, and Aug 12, 2019, we randomly assigned 1064 couples to intracytoplasmic sperm injection (n=532) or conventional IVF (n=532). Livebirth after the first embryo transfer from the initiated cycle occurred in 184 (35%) of 532 couples randomly assigned to intracytoplasmic sperm injection and in 166 (31%) of 532 couples randomly assigned to conventional IVF (absolute difference 3·4%, 95% CI -2·4 to 9·2; risk ratio [RR] 1·11, 95% CI 0·93 to 1·32; p=0·27). 29 (5%) couples in the intracytoplasmic sperm injection group and 34 (6%) couples in the conventional IVF group had fertilisation failure (absolute difference -0·9%, -4·0 to 2·1, RR 0·85, 95% CI 0·53 to 1·38; p=0·60).
INTERPRETATION: In couples with infertility in whom the male partner has a normal total sperm count and motility, intracytoplasmic sperm injection did not improve the livebirth rate compared with conventional IVF. Our results challenge the value of the routine use of intracytoplasmic sperm injection in assisted reproduction techniques for this population. FUNDING: My Duc Hospital and Merck Sharp and Dohme.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33894833     DOI: 10.1016/S0140-6736(21)00535-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

1.  Placental histology and pregnancy complications following intracytoplasmic sperm injection for non-male factor infertility.

Authors:  Hadas Ganer Herman; Alexander Volodarsky-Perel; Tuyet Nhung Ton Nu; Alexandre Machado-Gedeon; Yiming Cui; Jonathan Shaul; Michael H Dahan
Journal:  J Assist Reprod Genet       Date:  2022-03-21       Impact factor: 3.357

Review 2.  Epigenetic Risks of Medically Assisted Reproduction.

Authors:  Romualdo Sciorio; Nady El Hajj
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

3.  Effect of post-warming culture time on the live birth rate after frozen embryo transfer.

Authors:  Huy H Pham; Trinh M Vu; Chau H Nguyen; Anh H Le; Dung P Nguyen; Toan D Pham; Tuong M Ho; Lan N Vuong
Journal:  Reprod Med Biol       Date:  2022-05-30

4.  Prediction of Fertilization Disorders in the In Vitro Fertilization/Intracytoplasmic Sperm Injection: A Retrospective Study of 106,728 Treatment Cycles.

Authors:  Tian Tian; Lixue Chen; Rui Yang; Xiaoyu Long; Qin Li; Yongxiu Hao; Fei Kong; Rong Li; Yuanyuan Wang; Jie Qiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-20       Impact factor: 6.055

5.  Differences in ICSI utilization rates among states with insurance mandates for ART coverage.

Authors:  Pavel Zagadailov; Kyung S Cho; David B Seifer
Journal:  Reprod Biol Endocrinol       Date:  2021-11-30       Impact factor: 5.211

Review 6.  Contemporary Use of ICSI and Epigenetic Risks to Future Generations.

Authors:  Romualdo Sciorio; Sandro C Esteves
Journal:  J Clin Med       Date:  2022-04-11       Impact factor: 4.964

Review 7.  Opportunities and Limits of Conventional IVF versus ICSI: It Is Time to Come off the Fence.

Authors:  Martina Balli; Anna Cecchele; Valerio Pisaturo; Sofia Makieva; Giorgia Carullo; Edgardo Somigliana; Alessio Paffoni; Paola Vigano'
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

8.  Global inequality in sub-fertility treatment needs safer, cost effective, evidence-based and economically viable choices for patients and stakeholders.

Authors:  Gulam Bahadur; Roy Homburg; Asif Muneer; Paul Racich; Kanna Jayaprakasan; Santanu Acharya; Eric Jauniaux
Journal:  JBRA Assist Reprod       Date:  2022-01-17

9.  Should rescue ICSI be re-evaluated considering the deferred transfer of cryopreserved embryos in in-vitro fertilization cycles? A systematic review and meta-analysis.

Authors:  Alessio Paffoni; Marco Reschini; Valerio Pisaturo; Cristina Guarneri; Simone Palini; Paola Viganò
Journal:  Reprod Biol Endocrinol       Date:  2021-08-04       Impact factor: 5.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.